Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Pfizer’s Pandemic Success Finally Prompts A Transaction
Executive Summary
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.